U.S. flag

An official website of the United States government

Filters

See more specimen types...
See more states

Other countries

Results: 21 to 40 of 73

Tests names and labsConditionsGenes, analytes, and microbesMethods

Endeavor

PathGroup
United States
73505
  • C Sequence analysis of the entire coding region

Comprehensive Myeloid Profile + CALR PCR + FLT3 PCR

PathGroup
United States
1665
  • T Targeted variant analysis

OmniSeq INSIGHT

OmniSeq, Inc.
United States
1525
  • R RNA analysis
  • C Sequence analysis of the entire coding region

GTC-Solid Tumor Profile Plus Fusion/Expression (DNA and RNA)

Genomic Testing Cooperative, LCA
United States
1434
  • R RNA analysis
  • C Sequence analysis of the entire coding region

GTC-Solid Tumor Profile

Genomic Testing Cooperative, LCA
United States
1434
  • C Sequence analysis of the entire coding region

Myelodysplastic syndrome, somatic, 614286 (Myelodysplastic syndrome) (SF3B1 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Comprehensive HemeComplete Profile with IGH Somatic Hypermutation

PathGroup
United States
13161
  • E Sequence analysis of select exons
  • T Targeted variant analysis

HemeComplete NextGen Sequencing Assay with Calreticulin Exon 9 Mutation, FLT3 ITD and TKD Analysis and T-Cell Clonality Analysis

PathGroup
United States
23160
  • T Targeted variant analysis

HemeComplete NextGen Sequencing Assay with Calreticulin Exon 9 Mutation, FLT3 ITD and TKD Analysis and JAK2 V617F Quant

PathGroup
United States
18160
  • T Targeted variant analysis

Comprehensive HemeComplete Profile + CALR PCR + FLT3 PCR + BCR/ABL1 IS

PathGroup
United States
17160
  • T Targeted variant analysis

Comprehensive HemeComplete Profile + CALR PCR + FLT3 PCR + BCR/ABL1

PathGroup
United States
17160
  • T Targeted variant analysis

Comprehensive HemeComplete Profile + CALR PCR + FLT3 PCR

PathGroup
United States
16160
  • T Targeted variant analysis

Myeloid MPN/MDS/CMML Comprehensive Panel​, Sequencing

Providence St. Joseph Health Molecular Genomics Laboratory Providence St Joseph Health
United States
135
  • E Sequence analysis of select exons

NeoTYPE® Discovery Profile for Solid Tumors

NeoGenomics Laboratories NeoGenomics Laboratories, Inc.
United States
1315
  • I Immunohistochemistry
  • F Fluorescence in situ hybridization (FISH)
  • C Sequence analysis of the entire coding region

ProvSeq 523

Providence St. Joseph Health Molecular Genomics Laboratory Providence St Joseph Health
United States
1523
  • C Sequence analysis of the entire coding region

Myeloid neoplasms panel

Molecular Genetics Laboratory North York General Hospital
Canada
542
  • C Sequence analysis of the entire coding region

Comprehensive Hematologic Cancer Panel

Genomic Diagnostic Laboratory, Division of Genomic Diagnostics Children's Hospital of Philadelphia
United States
2215
  • D Deletion/duplication analysis
  • R RNA analysis
  • C Sequence analysis of the entire coding region

Comprehensive Solid Tumor Panel

Genomic Diagnostic Laboratory, Division of Genomic Diagnostics Children's Hospital of Philadelphia
United States
2315
  • D Deletion/duplication analysis
  • R RNA analysis
  • C Sequence analysis of the entire coding region

Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing

ARUP Laboratories, Molecular Oncology ARUP Laboratories
United States
665
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Myeloproliferative / myelodysplastic syndrome [detection of somatic mutations: JAK2 (V617F and exon 12), CALR (exon 9) , MPL (exon 10), ASXL1 (exon 13), CBL (exons 8 and 9), CSF3R (exons 14 – 17), DNMT3A (whole coding region), ETNK1 (exon 3), EZH2 (whole

CGC Genetics Unilabs
Portugal
315
  • E Sequence analysis of select exons

Results: 21 to 40 of 73

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.